StudioAlpha invested in MoleculeMind, a computational biology company developing methods for GPCR-targeted therapeutics using physics-conditioned generation and structure-based methodologies.
Added recently
MoleculeMind is an AI-driven biotechnology company focused on de novo design and structural optimization of proteins for therapeutic and industrial applications
MoleculeMind is an AI-driven biotechnology company focused on de novo design and structural optimization of proteins for therapeutic and industrial applications. Their MoleculeOS® AI platform enhances the performance characteristics of macromolecules, enabling the development of next-generation therapeutics and high-performance industrial proteins.